Status:
UNKNOWN
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
Lead Sponsor:
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborating Sponsors:
The First Affiliated Hospital of Soochow University
Conditions:
T-ALL
Eligibility:
All Genders
12-65 years
Phase:
NA
Brief Summary
Patients with acute leukemia derived from T lymphocytes have the characteristics of high expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to genetically modify t...
Eligibility Criteria
Inclusion
- Age 12-65
- Sign informed consent
- Expected survival time ≥ 3 months
- CD7 positive refractory and relapsed acute leukemia
- Karnofsky score≥60
- ECOG score ≤ 2
- Have not received other immunotherapy within 3 months
- The CD7 expression rate on the surface of leukemia cells detected by flow cytometry is greater than 30%
Exclusion
- Uncontrolled active infection
- Active viral hepatitis B or C
- HIV test positive
- Congenital immunodeficiency patients
- Pregnant and breastfeeding patients
- Patients with central nervous system tumors or central nervous system leukemia
- The patient and/or family members do not agree to the treatment plan
Key Trial Info
Start Date :
March 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 4 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04785833
Start Date
March 4 2021
End Date
February 4 2024
Last Update
March 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliared Hospital Of SOOCHOW University
Suzhou, Jiangsu, China, 215006